|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: AGK |
Gene summary for AGK |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | AGK | Gene ID | 55750 |
| Gene name | acylglycerol kinase | |
| Gene Alias | CATC5 | |
| Cytomap | 7q34 | |
| Gene Type | protein-coding | GO ID | GO:0006605 | UniProtAcc | A4D1U5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55750 | AGK | LZE4T | Human | Esophagus | ESCC | 1.51e-08 | 2.68e-01 | 0.0811 |
| 55750 | AGK | LZE7T | Human | Esophagus | ESCC | 1.83e-12 | 4.55e-01 | 0.0667 |
| 55750 | AGK | LZE8T | Human | Esophagus | ESCC | 2.25e-03 | 1.79e-01 | 0.067 |
| 55750 | AGK | LZE20T | Human | Esophagus | ESCC | 1.26e-05 | 2.29e-01 | 0.0662 |
| 55750 | AGK | LZE24T | Human | Esophagus | ESCC | 2.74e-10 | 2.04e-01 | 0.0596 |
| 55750 | AGK | P1T-E | Human | Esophagus | ESCC | 1.22e-03 | 2.56e-01 | 0.0875 |
| 55750 | AGK | P2T-E | Human | Esophagus | ESCC | 2.87e-15 | 1.98e-01 | 0.1177 |
| 55750 | AGK | P4T-E | Human | Esophagus | ESCC | 5.05e-23 | 4.81e-01 | 0.1323 |
| 55750 | AGK | P5T-E | Human | Esophagus | ESCC | 7.13e-22 | 4.00e-01 | 0.1327 |
| 55750 | AGK | P8T-E | Human | Esophagus | ESCC | 7.46e-18 | 2.71e-01 | 0.0889 |
| 55750 | AGK | P9T-E | Human | Esophagus | ESCC | 8.68e-12 | 2.56e-01 | 0.1131 |
| 55750 | AGK | P10T-E | Human | Esophagus | ESCC | 1.88e-22 | 4.35e-01 | 0.116 |
| 55750 | AGK | P11T-E | Human | Esophagus | ESCC | 6.27e-07 | 2.44e-01 | 0.1426 |
| 55750 | AGK | P12T-E | Human | Esophagus | ESCC | 3.28e-23 | 4.31e-01 | 0.1122 |
| 55750 | AGK | P15T-E | Human | Esophagus | ESCC | 1.09e-27 | 5.18e-01 | 0.1149 |
| 55750 | AGK | P16T-E | Human | Esophagus | ESCC | 7.21e-14 | 3.04e-01 | 0.1153 |
| 55750 | AGK | P19T-E | Human | Esophagus | ESCC | 2.47e-08 | 6.02e-01 | 0.1662 |
| 55750 | AGK | P20T-E | Human | Esophagus | ESCC | 8.00e-05 | 1.74e-01 | 0.1124 |
| 55750 | AGK | P21T-E | Human | Esophagus | ESCC | 7.12e-14 | 3.45e-01 | 0.1617 |
| 55750 | AGK | P22T-E | Human | Esophagus | ESCC | 2.12e-12 | 1.92e-01 | 0.1236 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0072594110 | Esophagus | ESCC | establishment of protein localization to organelle | 311/8552 | 422/18723 | 3.02e-32 | 2.13e-29 | 311 |
| GO:0006605111 | Esophagus | ESCC | protein targeting | 229/8552 | 314/18723 | 4.93e-23 | 1.01e-20 | 229 |
| GO:0006839110 | Esophagus | ESCC | mitochondrial transport | 187/8552 | 254/18723 | 8.35e-20 | 9.81e-18 | 187 |
| GO:0090150110 | Esophagus | ESCC | establishment of protein localization to membrane | 182/8552 | 260/18723 | 1.27e-15 | 8.19e-14 | 182 |
| GO:0072655110 | Esophagus | ESCC | establishment of protein localization to mitochondrion | 97/8552 | 120/18723 | 2.17e-15 | 1.33e-13 | 97 |
| GO:0070585110 | Esophagus | ESCC | protein localization to mitochondrion | 100/8552 | 125/18723 | 2.96e-15 | 1.77e-13 | 100 |
| GO:000700619 | Esophagus | ESCC | mitochondrial membrane organization | 93/8552 | 116/18723 | 2.16e-14 | 1.11e-12 | 93 |
| GO:0006626110 | Esophagus | ESCC | protein targeting to mitochondrion | 81/8552 | 100/18723 | 3.60e-13 | 1.67e-11 | 81 |
| GO:005120515 | Esophagus | ESCC | protein insertion into membrane | 46/8552 | 57/18723 | 5.90e-08 | 1.04e-06 | 46 |
| GO:00066433 | Esophagus | ESCC | membrane lipid metabolic process | 130/8552 | 203/18723 | 9.29e-08 | 1.54e-06 | 130 |
| GO:009015118 | Esophagus | ESCC | establishment of protein localization to mitochondrial membrane | 26/8552 | 30/18723 | 3.79e-06 | 4.12e-05 | 26 |
| GO:000700713 | Esophagus | ESCC | inner mitochondrial membrane organization | 31/8552 | 38/18723 | 5.93e-06 | 6.10e-05 | 31 |
| GO:00464673 | Esophagus | ESCC | membrane lipid biosynthetic process | 91/8552 | 142/18723 | 7.19e-06 | 7.19e-05 | 91 |
| GO:00066652 | Esophagus | ESCC | sphingolipid metabolic process | 96/8552 | 155/18723 | 3.21e-05 | 2.66e-04 | 96 |
| GO:005120416 | Esophagus | ESCC | protein insertion into mitochondrial membrane | 21/8552 | 25/18723 | 9.12e-05 | 6.54e-04 | 21 |
| GO:00442626 | Esophagus | ESCC | cellular carbohydrate metabolic process | 160/8552 | 283/18723 | 1.43e-04 | 9.66e-04 | 160 |
| GO:00464864 | Esophagus | ESCC | glycerolipid metabolic process | 211/8552 | 392/18723 | 6.51e-04 | 3.46e-03 | 211 |
| GO:19011362 | Esophagus | ESCC | carbohydrate derivative catabolic process | 99/8552 | 172/18723 | 1.11e-03 | 5.54e-03 | 99 |
| GO:00450393 | Esophagus | ESCC | protein insertion into mitochondrial inner membrane | 11/8552 | 12/18723 | 1.26e-03 | 6.06e-03 | 11 |
| GO:00442827 | Esophagus | ESCC | small molecule catabolic process | 201/8552 | 376/18723 | 1.35e-03 | 6.41e-03 | 201 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| AGK | SNV | Missense_Mutation | rs770192933 | c.968N>C | p.Asp323Ala | p.D323A | Q53H12 | protein_coding | tolerated(0.15) | benign(0.022) | TCGA-A2-A04Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| AGK | SNV | Missense_Mutation | rs770192933 | c.968N>C | p.Asp323Ala | p.D323A | Q53H12 | protein_coding | tolerated(0.15) | benign(0.022) | TCGA-A2-A0D0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
| AGK | SNV | Missense_Mutation | rs770192933 | c.968A>C | p.Asp323Ala | p.D323A | Q53H12 | protein_coding | tolerated(0.15) | benign(0.022) | TCGA-A2-A0T2-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | xeloda | PD |
| AGK | SNV | Missense_Mutation | rs770192933 | c.968N>C | p.Asp323Ala | p.D323A | Q53H12 | protein_coding | tolerated(0.15) | benign(0.022) | TCGA-A2-A0YE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Taxotere | SD |
| AGK | SNV | Missense_Mutation | rs770192933 | c.968N>C | p.Asp323Ala | p.D323A | Q53H12 | protein_coding | tolerated(0.15) | benign(0.022) | TCGA-A2-A25F-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD |
| AGK | SNV | Missense_Mutation | rs770192933 | c.968N>C | p.Asp323Ala | p.D323A | Q53H12 | protein_coding | tolerated(0.15) | benign(0.022) | TCGA-A8-A06R-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR |
| AGK | SNV | Missense_Mutation | rs770192933 | c.968A>C | p.Asp323Ala | p.D323A | Q53H12 | protein_coding | tolerated(0.15) | benign(0.022) | TCGA-A8-A095-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
| AGK | SNV | Missense_Mutation | novel | c.711T>G | p.Phe237Leu | p.F237L | Q53H12 | protein_coding | tolerated(0.64) | benign(0.001) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| AGK | SNV | Missense_Mutation | c.352N>A | p.Val118Met | p.V118M | Q53H12 | protein_coding | tolerated(0.25) | benign(0.007) | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| AGK | SNV | Missense_Mutation | c.50N>G | p.Ala17Gly | p.A17G | Q53H12 | protein_coding | tolerated(0.06) | benign(0.017) | TCGA-AR-A24Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |